Securities Lawsuits Filed Against Doximity, Ryde, Unicycive
Securities Lawsuits Filed Against Doximity, Ryde, Unicycive
Anonymous
Key Points
1
Doximity operates a digital platform for U.S. medical professionals that combines health-care news, workflow tools and clinician networking, and is often characterized as the “LinkedIn for doctors.”
2
According to the complaint, nearly all of Doximity’s revenue comes through its Marketing Solutions segment, which sells digital advertising subscriptions to pharmaceutical companies and hospitals.
3
The complaint alleges that Doximity told investors its Newsfeed was “both our most used and most monetized product,” was “reaching new highs,” and had achieved records in quarterly active prescribers and article engagement.
4
The complaint also alleges that Doximity assured investors it did not “bombard physicians with ads and messages” and claimed that it did not have an e-newsletter product, despite allegedly relying substantially on email newsletters and banner advertising.
5
The lawsuit notice says investors seeking to serve as lead plaintiff must act by Nov. 16, 2026; the notice states that investors may pursue the case even if they still hold their shares and that participation carries no cost or obligation.
Bernstein Liebhard reports that a federal securities class-action lawsuit has been filed against Doximity, Inc., alleging the medical platform misled investors about its Newsfeed advertising product and hid competitive pressures. The complaint claims Doximity overstated Newsfeed as its largest revenue driver while actually relying more on banner ads and email newsletters. Stock fell 23% in May 2026, triggering the alleged corrective disclosures that sparked investor losses.
The lawsuit covers investors who bought Doximity shares between August 8, 2024, and May 13, 2026. Bragar Eagel & Squire is leading the class action and says investors must act by November 16, 2026, to seek lead plaintiff status—at no cost or obligation, even if they still hold their shares.
What Doximity Told Investors About Newsfeed
Doximity, often called the "LinkedIn for doctors," operates a platform where U.S. medical professionals access health-care news, workflow tools, and clinician networking. The company's nearly all revenue flows through its Marketing Solutions segment, which sells digital advertising subscriptions to pharmaceutical companies and hospitals.
Bragar Eagel & Squire says the complaint alleges Doximity told investors that Newsfeed was "both our most used and most monetized product" and was "reaching new highs." The company also claimed it hit records in quarterly active prescribers and article engagement. But Bernstein Liebhard notes the lawsuit says these claims were false.
The Hidden Reliance on Email and Banner Ads
According to Bragar Eagel & Squire, the complaint alleges Doximity assured investors it did not "bombard physicians with ads and messages" and claimed it had no e-newsletter product at all. Yet the lawsuit says Doximity actually relied substantially on email newsletters and banner advertising—products it publicly downplayed or denied.
This disconnect matters because advertisers care about reach and engagement. By hiding its true reliance on email and banner ads, Doximity may have misled investors about its actual competitive position. The lawsuit alleges competitors offered more attractive pricing and better engagement models, eating into Doximity's market share.
Timeline of Stock Decline and Disclosure
The lawsuit identifies corrective disclosures between November 2025 and May 2026 as the turning point. Bernstein Liebhard reports that Doximity's stock dropped 23% in May 2026 alone, suggesting the market reacted sharply to the truth about Newsfeed's actual performance and the company's hidden ad dependencies.
Investors who purchased Doximity shares from August 8, 2024, through May 13, 2026, are eligible to join the class. Bragar Eagel & Squire reminds investors they must notify the firm by November 16, 2026, to pursue lead plaintiff status. No cost or share ownership requirement applies.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
41
Reach
60
A
AnonymousAuthor
